Physician profile
Michael Duke
NPI 1689609877
$6,117.69
in general payments reported to CMS, 2019-2025
40 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $913 · 2021: $675 · 2022: $695 · 2023: $818 · 2024: $1,180 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $747.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $522.78 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $476.46 | 2021-2025 | |
| Amgen INC. | $432.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $332.99 | 2019-2025 | |
| Lilly USA, LLC | $328.46 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Sanofi-Aventis U.S. LLC | $285.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $238.32 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $210.91 | 2019-2021 | |
| Exact Sciences Corporation | $203.93 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $179.21 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.60 | 2019-2024 | Jardiance |
| Abbott Laboratories | $137.30 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $102.69 | 2021-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.